{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:09:50Z","timestamp":1771916990868,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1126,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Hepatocellular carcinoma (HCC) is potentially curable with hepatic resection or transplantation. Few patients are eligible for resection, and many face a long wait for donor organ availability for liver transplantation. Here we report the safety and efficacy of stereotactic body radiation therapy (SBRT), the explant pathology findings and survival of patients treated with SBRT as a bridge to transplantation for HCC. From April 2005 to August 2010, 10 patients with 11 HCCs were treated with SBRT as a bridge to transplantation. All patients were evaluated by a liver transplant surgeon before radiosurgery. SBRT was delivered with the CyberKnife robotic radiosurgery system. After SBRT, all patients underwent orthotopic liver transplantation. The tumor response was determined by explant pathology. The median follow-up was 62 months from the time of SBRT. The mean time on the liver transplant wait list was 163 days. The median tumor size was 3.4 cm (range = 2.5-5.5 cm). The median SBRT dose was 51 Gy (range = 33-54 Gy) in 3 fractions. The median time from SBRT to liver transplantation was 113 days (range = 8-794 days). At 5 years, the overall survival rate and the disease-free survival rate were both 100%. Overall, 4 of the 10 patients (40%) experienced acute toxicity. Most toxicities were grade 1, and they included nausea, fatigue, and abdominal discomfort. One patient had grade 2 nausea\/vomiting. Explant pathology revealed no viable tumor in 3 of the 11 tumors for a complete response rate of 27%. The remaining 8 tumors decreased or remained stable in size. In conclusion, with a median follow-up over 5 years, we have found that SBRT as a bridge to liver transplantation for HCC is feasible and well tolerated. SBRT for HCC may enable patients to remain on the list for frequently curative transplantation during the wait for organ availability. Liver Transpl, 2012. \u00a9 2012 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23439","type":"journal-article","created":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T06:42:28Z","timestamp":1333262548000},"page":"949-954","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":132,"title":["Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"John K.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran B.","family":"Klintmalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"621630","DOI":"10.1002\/lt.20159","article-title":"Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of EndStage Liver Disease (MELD) organ allocation policy.","volume":"10","author":"Yao","year":"2004","journal-title":"Liver Transpl"},{"key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"873883","DOI":"10.1053\/jlts.2002.34923","article-title":"Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intentiontotreat principle and dropout from the waiting list.","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transpl"},{"key":"R3-11-20250124","doi-asserted-by":"crossref","first-page":"14341440","DOI":"10.1002\/hep.510300629","article-title":"Intentiontotreat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"15051514","DOI":"10.1002\/lt.20526","article-title":"A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.","volume":"11","author":"Yao","year":"2005","journal-title":"Liver Transpl"},{"key":"R5-11-20250124","doi-asserted-by":"crossref","first-page":"18751881","DOI":"10.1111\/j.1600-6143.2007.01863.x","article-title":"Treatment of HCC in patients awaiting liver transplantation.","volume":"7","author":"Schwartz","year":"2007","journal-title":"Am J Transplant"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"311322","DOI":"10.1055\/s-2007-1007120","article-title":"Liver transplantation for hepatocellular carcinoma.","volume":"19","author":"Bismuth","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"643653","DOI":"10.7326\/0003-4819-129-8-199810150-00013","article-title":"Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.","volume":"129","author":"Mor","year":"1998","journal-title":"Ann Intern Med"},{"key":"R8-11-20250124","doi-asserted-by":"crossref","first-page":"130138","DOI":"10.1245\/ASO.2004.10.907","article-title":"Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors.","volume":"11","author":"Fuss","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"R9-11-20250124","first-page":"15721578","article-title":"Multiinstitutional phase III trial of stereotactic body radiation therapy for liver metastases.","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-11-20250124","doi-asserted-by":"crossref","first-page":"164170","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic singledose radiation therapy of liver tumors: results of a phase III trial.","volume":"19","author":"Herfarth","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-11-20250124","doi-asserted-by":"crossref","first-page":"576580","DOI":"10.1097\/01.coc.0000184657.65679.6f","article-title":"Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy.","volume":"28","author":"Kelsey","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"R12-11-20250124","doi-asserted-by":"crossref","first-page":"810821","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiationinduced liver disease using the Lyman NTCP model.","volume":"53","author":"Dawson","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"271277","DOI":"10.1016\/j.semradonc.2011.05.002","article-title":"Radiation therapy for hepatocellular carcinoma.","volume":"21","author":"Feng","year":"2011","journal-title":"Semin Radiat Oncol"},{"key":"R14-11-20250124","first-page":"5869","article-title":"Stereotactic body radiation therapy for liver primary and metastases: the Lille experience in French.","volume":"16","author":"Dewas","year":"2012","journal-title":"Cancer Radiother"},{"key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"888893","DOI":"10.1007\/s00270-007-9111-9","article-title":"Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.","volume":"30","author":"Stockland","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"13321338","DOI":"10.1016\/j.jhep.2011.03.024","article-title":"Embolization of hepatocellular carcinoma with drugeluting beads: doxorubicin tissue concentration and distribution in patient liver explants.","volume":"55","author":"Namur","year":"2011","journal-title":"J Hepatol"},{"key":"R19-11-20250124","first-page":"28782882","article-title":"Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R20-11-20250124","doi-asserted-by":"crossref","first-page":"914921","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R21-11-20250124","doi-asserted-by":"crossref","first-page":"23862393","DOI":"10.1002\/1097-0142(20010615)91:12<2386::AID-CNCR1272>3.0.CO;2-4","article-title":"Association between insulinlike growth factor2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study.","volume":"91","author":"Song","year":"2001","journal-title":"Cancer"},{"key":"R22-11-20250124","doi-asserted-by":"crossref","first-page":"160166","DOI":"10.1046\/j.1365-2559.2001.01064.x","article-title":"Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization.","volume":"38","author":"Kim","year":"2001","journal-title":"Histopathology"},{"key":"R23-11-20250124","doi-asserted-by":"crossref","first-page":"594601","DOI":"10.1634\/theoncologist.2010-0292","article-title":"Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost.","volume":"16","author":"Whitney","year":"2011","journal-title":"Oncologist"},{"key":"R24-11-20250124","doi-asserted-by":"crossref","first-page":"494498","DOI":"10.1097\/COC.0b013e3181ec63ae","article-title":"Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable nonsmallcell lung cancer.","volume":"34","author":"Lanni","year":"2011","journal-title":"Am J Clin Oncol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201208000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:16:15Z","timestamp":1737738975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201208000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23439","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}